Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 11111277
Influenza vaccines
granted -
US 11111222
Hydroxyeicosatrienoic acid compounds and their use as therapeutic agents
granted -
US 11110128
Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo
granted -
US 11110177
ASH1L degraders and methods of treatment therewith
granted -
US 11110080
Small molecule inhibitors of bacterial efflux pumps and methods of using same
granted -
US 11111375
Compositions and methods for generating oligodendrocyte precursors
granted -
US 11104706
Ang (1-7) derivative oligopeptides and methods for using and producing the same
granted -
US 11103520
Analogs of N-acetlyglucosamine and uses thereof
granted -
US 11103436
Peptide exhibiting wrinkle-improving activity and uses thereof
granted -
US 11103622
Thromboresistant/bactericidal s-nitroso-n-acetylpenicillamine (SNAP)-doped nitric oxide release polymers with enhanced stability
granted -
US 11104704
Peptide having cytoprotective effect against environmental pollutant and use thereof
granted -
US 11103460
Fabrication methods for nanodelivery systems for long term controlled delivery of active pharmaceutical ingredients
granted -
US 11104719
Recombinant clusterin and use thereof in the treatment and prevention of disease
granted -
US 11104684
Dimers of covalent NFKB inhibitors
granted -
US 11103462
Protein nanocapsules with detachable zwitterionic coating for protein delivery
granted -
US 11098150
Block copolymer and micelle compositions and methods of use thereof
granted -
US 11099172
In vitro assays for inhibition of microglial activation
granted -
US 11096965
Compositions and methods related to polycytotoxic T cells
granted -
US 11096997
Scaffolds for cell transplantation
granted -
US 11096900
Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
granted -
US 11097017
Gadolinium-based contrast agents for sensitive detection of Zn2+with MRI
granted -
US 11096966
Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo
granted -
US 11098052
4-azapodophylotoxins compounds
granted -
US 11097012
Biodegradable vectors for efficient RNA delivery
granted -
US 11098100
Therapeutic compounds and methods
granted -
US 11098101
Therapeutic compounds and methods
granted -
US 11098082
Antigenic peptides and uses thereof for diagnosing and treating autism
granted -
US 11098109
Single-chain variable fragment anti-CD133 antibodies and uses thereof
granted -
US 11096910
Metabolically robust analogs of CYP-eicosanoids for the treatment of cardiac disease
granted -
US 11097034
Compositions and methods of modulating endochondral ossification and bone formation
granted -
US 11091516
Synthetic binder of breast cancer stem cells
granted -
US 11091529
Peptides having reduced toxicity that stimulate cholesterol efflux
granted -
US 11091795
Compositions and methods for diagnosing and treating arrhythmias
granted -
US 11090311
Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer
granted -
US 11090286
Methods of treating and preventing breast cancer with S-equol
granted -
US 11090310
Methods and compositions for treating hypertriglyceridemia
granted -
US 11091472
PI-kinase inhibitors with anti-infective activity
granted -
US 11090344
Adenovirus and immunomodulator combination therapy
granted -
US 11090332
Antigen specific mRNA cellular cancer vaccines
granted -
US 11083708
Pharmacological restoration of epithelial or endothelial barrier integrity by agents blocking EPAC/RAP1 signaling
granted -
US 11083736
Compositions comprising triterpenoids
granted -
US 11086049
Anti-microbial bandage contact lens with ocular drug delivery
granted -
US 11085057
Compositions and methods for modifying a target nucleic acid
granted -
US 11083788
Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
granted -
US 11083753
Targeted replacement of endogenous T cell receptors
granted -
US 11084795
CFTR regulators and methods of use thereof
granted -
US 11084869
Antibody-mediated neutralization of Marburg virus
granted -
US 11083720
Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory